Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Cetuximab and Bevacizumab in Esophageal Carcinoma That Failed First Line Therapy

NCT00636298 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT00636298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00636298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Cetuximab and Bevacizumab in Esophageal Carcinoma That Failed First Line Therapy
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Withdrawn
Start date
October 31, 2008
Completion date
March 31, 2012
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal carcinoma